Please use this identifier to cite or link to this item: https://hdl.handle.net/2440/8070
Citations
Scopus Web of ScienceĀ® Altmetric
?
?
Full metadata record
DC FieldValueLanguage
dc.contributor.authorKennaway, D.-
dc.contributor.authorRowe, S.-
dc.contributor.authorFerguson, S.-
dc.date.issued1996-
dc.identifier.citationBrain Research, 1996; 737(1-2):301-307-
dc.identifier.issn0006-8993-
dc.identifier.issn1872-6240-
dc.identifier.urihttp://hdl.handle.net/2440/8070-
dc.description.abstractThe effect of serotonin agonists on the rhythmic excretion of the melatonin metabolite 6-sulphatoxymelatonin was examined in rats. The animals were maintained in 12L:12D and administered saline, quipazine (10 mg/kg), (+/-)-2-propylamino-8-hydroxy-1,2,3,4-tetrahydronaphthalene hydrobromide (8-OH-DPAT, 5 mg/kg) or buspirone (10 mg/kg), 4 h after dark (ZT16). All three drugs caused an acute, transient suppression of 6-sulphatoxymelatonin excretion and a significant delay (P < 0.01) in the onset of the nocturnal rise on the following night of 2.1 +/- 0.6, 1.4 +/- 0.7 and 1.5 +/- 0.3 h respectively while saline administration had no effect (0.4 +/- 0.2 h delay, P > 0.01). To examine the effects of the time of day of agonist administration, groups of rats were treated with quipazine (10 mg/kg) or 8-OH-DPAT (5 mg/kg) 18, 24 or 30 h after the initiation of continuous darkness (CT6, CT12 or CT18) and monitored for a further two nights. Quipazine but not 8-OH-DPAT injection at CT6 resulted in a small but significant delay in the onset of 6-sulphatoxymelatonin excretion on the following night (1.0 +/- 0.2 h and 0.3 +/- 0.2 h) while treatment with both agonists at CT12 failed to affect the onset of excretion (0.8 +/- 0.2 and 0.1 +/- 0.2 h). When quipazine (10 mg/kg) was administered at CT18, 6-sulphatoxymelatonin excretion was acutely suppressed for the rest of the night and there was a large significant delay in the onset of 6-sulphatoxymelatonin excretion (1.2 +/- 0.2 h) while a smaller delay was observed following 8-OH-DPAT administration (0.8 +/- 0.2 h). The acute suppression of 6-sulphatoxymelatonin excretion and subsequent phase delay following quipazine treatment at CT18 was also evident at doses of 1 mg/kg (1.6 +/- 0.4 h) and 3 mg/kg (1.5 +/- 0.6 h). These results show that peripheral administration of serotonin agonists active at 5HT1a/5HT7 receptors mimic the dual effects of light on melatonin production in the rat and raise the possibility that serotonin pathways are more important in mediating the effects of retinally perceived light in the rat than previously believed.-
dc.language.isoen-
dc.publisherELSEVIER SCIENCE BV-
dc.source.urihttp://dx.doi.org/10.1016/0006-8993(96)00922-5-
dc.subjectAnimals-
dc.subjectRats-
dc.subjectRats, Wistar-
dc.subjectQuipazine-
dc.subjectBuspirone-
dc.subjectMelatonin-
dc.subject8-Hydroxy-2-(di-n-propylamino)tetralin-
dc.subjectCircadian Rhythm-
dc.subjectAdaptation, Ocular-
dc.subjectMale-
dc.subjectSerotonin Receptor Agonists-
dc.titleSerotonin agonists mimic the phase shifting effects of light on the melatonin rhythm in rats-
dc.typeJournal article-
dc.identifier.doi10.1016/0006-8993(96)00922-5-
pubs.publication-statusPublished-
dc.identifier.orcidKennaway, D. [0000-0002-5864-3514]-
Appears in Collections:Aurora harvest
Obstetrics and Gynaecology publications

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.